1.
Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A,
Saruhan-Direskeneli G: Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia
gravis. Neurology 2007, 68(8):609-611.
2.
Jani-Acsadi A, Lisak RP: Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007, 261(1-2):127-133.
3.
Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME,
Rowland LP: Myasthenic crisis: clinical features, mortality, complications, and risk factors for
prolonged intubation. Neurology 1997, 48(5):1253-1260.
4.
Keesey JC: "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve 2002, 26(1):1-3.
5.
Chaudhuri A, Behan PO: Myasthenic crisis. QJM 2009, 102(2):97-107.
6.
Cohen MS, Younger D: Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci 1981, 377:670-677.
7.
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ: Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009, 72(18):1548-1554.
8.
Ferguson IT, Murphy RP, Lascelles RG: Ventilatory failure in myasthenia gravis. J Neurol Neurosurg Psychiatry 1982, 45(3):217-222.
9.
Sharma S, Lal V, Prabhakar S, Agarwal R: Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective
study. Ann Indian Acad Neurol 2013, 16(2):203-207.
10.
Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS: Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit
results in a favourable long-term prognosis. Eur J Neurol 2014, 21(1):171-173.
11.
Bershad EM, Feen ES, Suarez JI: Myasthenia gravis crisis. South Med J 2008, 101(1):63-69.
12.
Wang W, Chen YP, Wang ZK, Wei DN, Yin L: A cohort study on myasthenia gravis patients in China. Neurol Sci 2013, 34(10):1759-1764.
13.
Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta
F, Simoncini O, Campanella A, Beghi E et al: Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003, 998:413-423.
14.
Sakaguchi H, Yamashita S, Hirano T, Nakajima M, Kimura E, Maeda Y, Uchino M: Myasthenic crisis patients who require intensive care unit management. Muscle Nerve 2012, 46(3):440-442.
15.
Bae JS, Go SM, Kim BJ: Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 2006, 13(10):1006-1010.
16.
Tomiyama M, Arai A, Kimura T, Suzuki C, Watanabe M, Kawarabayashi T, Shoji M: Exacerbation of chronic pancreatitis induced by anticholinesterase medications in
myasthenia gravis. Eur J Neurol 2008, 15(5):e40-41.
17.
Godoy DA, Mello LJ, Masotti L, Di Napoli M: The myasthenic patient in crisis: an update of the management in Neurointensive Care
Unit. Arq Neuropsiquiatr 2013, 71(9A):627-639.
18.
Lacomis D: Myasthenic crisis. Neurocrit Care 2005, 3(3):189-194.
19.
Plauche WC: Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991, 34(1):82-99.
20.
Gracey DR, Divertie MB, Howard FM, Jr.: Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience
with 22 patients. Mayo Clin Proc 1983, 58(9):597-602.
21.
Panda S, Goyal V, Behari M, Singh S, Srivastava T: Myasthenic crisis: a retrospective study. Neurol India 2004, 52(4):453-456.
22.
Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G: Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 1966, 16(5):431-439.
23.
Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA: Noninvasive ventilation in myasthenic crisis. Arch Neurol 2008, 65(1):54-58.
24.
Rabinstein A, Wijdicks EF: BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002, 59(10):1647-1649.
25.
Kiphuth IC, Schellinger PD, Kohrmann M, Bardutzky J, Lucking H, Kloska S, Schwab S,
Huttner HB: Predictors for good functional outcome after neurocritical care. Crit Care 2010, 14(4):R136.
26.
Cabrera Serrano M, Rabinstein AA: Usefulness of pulmonary function tests and blood gases in acute neuromuscular respiratory
failure. Eur J Neurol 2012, 19(3):452-456.
27.
Werneck LC, Scola RH, Germiniani FM, Comerlato EA, Cunha FM: Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr 2002, 60(3-A):519-526.
28.
Murthy JM, Meena AK, Chowdary GV, Naryanan JT: Myasthenic crisis: clinical features, complications and mortality. Neurol India 2005, 53(1):37-40; discussion 40.
29.
Lee CY, Lam CL, Pang SY, Lau KK, Teo KC, Chang RS, Chan KH: Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese. J Neuroimmunol 2015, 289:177-181.
30.
Liu C, Wang Q, Qiu Z, Lin J, Chen B, Li Y, Gui M, Zhang M, Yang M, Wang W et al: Analysis of mortality and related factors in 2195 adult myasthenia gravis patients
in a 10-year follow-up study. Neurol India 2017, 65(3):518-524.
31.
Fraisse T, Labauge P, Camu W, Arlaud P, de Wazieres B: [Myasthenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases]. Presse Med 2007, 36(1 Pt 1):9-14.
32.
Hoffmann S, Kohler S, Ziegler A, Meisel A: Glucocorticoids in myasthenia gravis - if, when, how, and how much? Acta Neurol Scand 2014, 130(4):211-221.
33.
Rozsa C, Mikor A, Kasa K, Illes Z, Komoly S: Long-term effects of combined immunosuppressive treatment on myasthenic crisis. Eur J Neurol 2009, 16(7):796-800.